Absorbable tissue spacer market to grow at 10% till 2029
September 07, 2019 - United States Of America
The global absorbable tissue spacer market reached nearly $85 million in value in 2018 and is expected to propel at a compounded annual growth rate of 10 per cent between 2019 and 2029, says a new study by US-based Future Market Insights (FMI). Rising demand for radiation therapy for cancer will be a key reason for that growth, says the study.
Stringent legal policies will persist to regulate the emission of high-energy rays during radiotherapy treatment and assure patient safety, which is likely to motivate manufacturers to perform clinical studies by consulting with experts.
Cancer specialists are constantly shifting towards absorbable tissue spacer to cure different types of cancers. Absorbable tissue spacers, after proper placement, protect the adjacent healthy tissues from strong radiation, resulting in increased concentration of dose delivery at the affected organ, thereby eliminating adverse procedural events. These also avoid the need for a second surgery for spacer removal as they gradually dissolve into the tissues.
Increasing prevalence of cancers continues to be a global concern, and elimination of cancerous tissues in an efficient way remains of core interest for oncologists and dosimetrists. The leading participants in absorbable tissue spacers market landscape are focusing on conducting clinical trials to develop spacers that are tailored to specific needs of the target area, says a released from the company.
As per the findings, hydrogel-based absorbable tissue spacers account for around three-fourths of the total sales. These are rapidly becoming an integral component of prostate cancer radiotherapy and are one of the few absorbable tissue spacers that have received government clearance in most countries.
Hydrogel-based spacers have high tolerability as the space created between prostate and rectum efficiently lowers the emission concentration on the rectum, significantly reducing irritation of rectum during prostate radiotherapy. Placing hydrogel-based spacers is technically less-complicated, especially for surgeons who are aware of ultrasound-directed transperineal injections.
Further, patients undergoing radiation therapy with hydrogel-based spacers are lesser prone to adverse long-term rectal complications and relatively decreased amount of rectal pain during treatment, making hydrogel-based spacer most sought-after among oncologists. (DS)
Stringent legal policies will persist to regulate the emission of high-energy rays during radiotherapy treatment and assure patient safety, which is likely to motivate manufacturers to perform clinical studies by consulting with experts.
Cancer specialists are constantly shifting towards absorbable tissue spacer to cure different types of cancers. Absorbable tissue spacers, after proper placement, protect the adjacent healthy tissues from strong radiation, resulting in increased concentration of dose delivery at the affected organ, thereby eliminating adverse procedural events. These also avoid the need for a second surgery for spacer removal as they gradually dissolve into the tissues.
Increasing prevalence of cancers continues to be a global concern, and elimination of cancerous tissues in an efficient way remains of core interest for oncologists and dosimetrists. The leading participants in absorbable tissue spacers market landscape are focusing on conducting clinical trials to develop spacers that are tailored to specific needs of the target area, says a released from the company.
As per the findings, hydrogel-based absorbable tissue spacers account for around three-fourths of the total sales. These are rapidly becoming an integral component of prostate cancer radiotherapy and are one of the few absorbable tissue spacers that have received government clearance in most countries.
Hydrogel-based spacers have high tolerability as the space created between prostate and rectum efficiently lowers the emission concentration on the rectum, significantly reducing irritation of rectum during prostate radiotherapy. Placing hydrogel-based spacers is technically less-complicated, especially for surgeons who are aware of ultrasound-directed transperineal injections.
Further, patients undergoing radiation therapy with hydrogel-based spacers are lesser prone to adverse long-term rectal complications and relatively decreased amount of rectal pain during treatment, making hydrogel-based spacer most sought-after among oncologists. (DS)